Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)

SEK 50.8

(-4.87%)

Market Cap (In SEK)

661.31 Million

Revenue (In SEK)

77 Thousand

Net Income (In SEK)

-123.06 Million

Avg. Volume

96.35 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
21.7-135.0
PE
-
EPS
-
Beta Value
1.036
ISIN
SE0008015259
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Staffan Stromberg Ph.D.
Employee Count
-
Website
https://www.ibtherapeutics.com
Ipo Date
2016-03-29
Details
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.